```
                4 REFERENCES IN FILE CA (1962 TO DATE)
                4 REFERENCES IN FILE CAPLUS (1962 TO DATE)


=> fil hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       158.63     158.84

FILE 'HCAPLUS' ENTERED AT 10:11:00 ON 15 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 15 Apr 2003  VOL 138 ISS 16
FILE LAST UPDATED: 14 Apr 2003  (20030414/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> s l3
L4           13 L3

=> s cancer or tumor or malignan? or carcinoma
         184787 CANCER
          25853 CANCERS
         192121 CANCER
                  (CANCER OR CANCERS)
         275098 TUMOR
         114634 TUMORS
         313429 TUMOR
                  (TUMOR OR TUMORS)
          58187 MALIGNAN?
          98795 CARCINOMA
          23123 CARCINOMAS
            157 CARCINOMATA
         105363 CARCINOMA
                  (CARCINOMA OR CARCINOMAS OR CARCINOMATA)
L5       471358 CANCER OR TUMOR OR MALIGNAN? OR CARCINOMA

=> s l4 and l5
L6            9 L4 AND L5

=> d ibib abs 5-9

L6   ANSWER 5 OF 9  HCAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:         2000:456916  HCAPLUS
DOCUMENT NUMBER:          133:68929
TITLE:                    Use of a matrix metalloproteinase inhibitor and an
                          integrin antagonist in the treatment of neoplasia
```

INVENTOR(S): McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L.
PATENT ASSIGNEE(S): G. D. Searle & Co., USA
SOURCE: PCT Int. Appl., 358 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038719	A1	20000706	WO 1999-US30700	19991222
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356402	AA	20000706	CA 1999-2356402	19991222
EP 1140183	A1	20011010	EP 1999-968942	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533407	T2	20021008	JP 2000-590670	19991222

PRIORITY APPLN. INFO.: US 1998-113786P P 19981223
WO 1999-US30700 W 19991222

AB Methods are provided to treat or prevent neoplasia disorders in a mammal using a combination of a matrix metalloproteinase inhibitor, an integrin antagonist, and an antineoplastic agent.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:456912 HCAPLUS
DOCUMENT NUMBER: 133:68927
TITLE: Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
INVENTOR(S): McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038715	A2	20000706	WO 1999-US30621	19991222
WO 2000038715	A3	20010104		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,				

AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2356748	AA	20000706	CA 1999-2356748	19991222
EP 1140177	A2	20011010	EP 1999-966558	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533404	T2	20021008	JP 2000-590666	19991222

PRIORITY APPLN. INFO.: US 1998-113786P P 19981223
WO 1999-US30621 W 19991222

AB Methods are provided to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.

L6 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:456866 HCAPLUS
DOCUMENT NUMBER: 133:84239
TITLE: Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
INVENTOR(S): McKearn, John P.; Gordon, Gary; Cunningham, James J.; Gately, Stephen T.; Koki, Alane T.; Masferrer, Jaime L.
PATENT ASSIGNEE(S): G. D. Searle & Co., USA
SOURCE: PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038665	A2	20000706	WO 1999-US30670	19991222
WO 2000038665	A3	20001116		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356462	AA	20000706	CA 1999-2356462	19991222
EP 1140193	A2	20011010	EP 1999-968529	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533387	T2	20021008	JP 2000-590619	19991222

PRIORITY APPLN. INFO.: US 1998-113786P P 19981223
WO 1999-US30670 W 19991222

AB The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of an integrin antagonist and an antineoplastic agent.

L6 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:31349 HCAPLUS
DOCUMENT NUMBER: 132:78853
TITLE: Preparation of [[[[(pyrimidinylamino)benzoyl]amino]acetyl]amino]benzenepropanoic acid derivatives as .alpha.v.beta.3 integrin antagonists
INVENTOR(S): Rogers, Thomas E.; Ruminski, Peter G.

PATENT ASSIGNEE(S): G. D. Searle & Co., USA
SOURCE: U.S., 33 pp., Cont.-in-part of U.S. Ser. No. 713,555.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6013651	A	20000111	US 1998-34758	19980304
US 6028223	A	20000222	US 1996-713555	19960827
TW 458956	B	20011011	TW 1996-85115118	19961206
US 6100423	A	20000808	US 1999-261822	19990303

PRIORITY APPLN. INFO.: US 1995-3277P P 19950830
US 1996-713555 A2 19960827
US 1998-34758 A2 19980304
OTHER SOURCE(S): MARPAT 132:78853
GI



I

AB Title compds. I (X, Y = halo, R = H, alkyl) or their pharmaceutically acceptable salts and isomers were prepd. as .alpha.v.beta.3 integrin antagonists. Thus, I (X = Cl, Y = Br, R = H), prepd. by coupling of 3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxypyrimidin-2-yl)amino]benzoic acid HCl salt with 3-bromo-5-chloro-2-hydroxy-.beta.-(glycylamino)benzenepropanoic acid Et ester HCl salt (syntheses given) and sapon., showed IC50 = 0.88 nM for inhibition of .alpha.v.beta.3 integrin.
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:576913 HCAPLUS
DOCUMENT NUMBER: 131:214295
TITLE: Preparation of meta-pyrimidinylamino benzamides and derivatives as .alpha.v.beta.3 integrin antagonists
INVENTOR(S): Rogers, Thomas E.; Ruminski, Peter G.
PATENT ASSIGNEE(S): G.D. Searle & Co., USA
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9944994	A1	19990910	WO 1999-US3281	19990222

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

ZA 9904406	A	20000211	ZA 1999-4406	19990211	
CA 2322207	AA	19990910	CA 1999-2322207	19990222	
AU 9932947	A1	19990920	AU 1999-32947	19990222	
AU 753230	B2	20021010			
BR 9908470	A	20001205	BR 1999-8470	19990222	
EP 1060164	A1	20001220	EP 1999-937927	19990222	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002505323	T2	20020219	JP 2000-534538	19990222	
EE 200000506	A	20020415	EE 2000-20000050	19990222	
NO 2000004316	A	20001106	NO 2000-4316	20000830	
PRIORITY APPLN. INFO.:			US 1998-34270 A	19980304	
			WO 1999-US3281 W	19990222	

OTHER SOURCE(S): MARPAT 131:214295

GI



I

AB Meta-pyrimidinylamino benzamides and derivs. (I) [R = H or lower alkyl; X and Y = the same of different halogens], and pharmaceutically acceptable salts and isomers thereof, were prepd. as .alpha.v.beta.3 integrin antagonists. Thus, 3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxypyrimidin-2-yl)amino]benzoic acid HCl (prepn. given) and Et (S)-3-bromo-5-chloro-.beta.-(glycylamino)-2-hydroxybenzenepropanoate HCl (prepn. given) were reacted in 4-dimethylaminopyridine, N,N-dimethylacetamide, and TEA followed by addn. of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide HCl and TFA to form the TFA salt of (S)-I (R = Et, X = Cl, Y = Br). The meta-pyrimidinylamino benzamide deriv. was deesterified with LiOH in H2O and MeCN to yield the TFA salt of (S)-I (R = H, X = Cl, Y = Br). Selected compds. were tested for .alpha.v.beta.3 integrin activity and exhibited IC50 values ranging from 0.37 to 23.7 nM in the vitronectin adhesion assay. IC50 values for compds. tested in the purified human fibrinogen IIb/IIIa receptor assay varied from 131 to 2440 nM. Inhibition of aggregation response for a series of test compd. was reported to have been evaluated in human platelet rich plasma assays (no data). Compds. of the invention are claimed to be useful for treatment of **tumor** metastasis, solid **tumor** growth, angiogenesis, osteoporosis, humoral hypercalcemia of **malignancy**, smooth muscle cell migration, restenosis, rheumatoid arthritis, and macular degeneration.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT